Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507246 | 0.84 | PTGS2 (0.34) | — | |
| SCHEMBL5507244 | 0.84 | PTGS2 (0.34) | — | |
| SCHEMBL4954649 | 0.81 | PTPN1 (0.49) | PTPN1PTGDR2 | |
| SCHEMBL5503559 | 0.80 | PTPN1 (0.41) | PTPN1PTGDR2 | |
| SCHEMBL5524348 | 0.80 | PTGS2 (0.35) | — | |
| SCHEMBL5503895 | 0.79 | PTPN1 (0.37) | PTPN1PTGDR2 | |
| SCHEMBL5504720 | 0.79 | PTPN1 (0.38) | PTPN1PTGDR2 | |
| SCHEMBL5500769 | 0.78 | PTPN1 (0.37) | PTPN1PTGDR2 | |
| SCHEMBL5503199 | 0.78 | PTPN1 (0.34) | PTPN1PTGDR2 | |
| SCHEMBL5986780 | 0.77 | PTPN1 (0.30) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | PTPN1 3/4885PTGDR2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.